Melanoma: open trials in France

62 open trials have a site in France. Registry data; only the trial team decides who can take part.

NCT07519655
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Trial Treatment · Phase 1 · Pfizer
Oncopole Claudius Regaud, Toulouse · Gustave Roussy, Villejuif
Registry updated 2026-11-05
NCT07492680
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Trial Treatment · Phase 2 · Bristol-Myers Squibb
Centre Georges François Leclerc, Dijon · Hopital Saint Louis, Paris · Pierre-Bénite · Villejuif
Registry updated 2026-11-04
NCT03340506
Dabrafenib and/or Trametinib Rollover Study
Trial Treatment · Phase 4 · Novartis Pharmaceuticals
Centre Leon Berard, Lyon · Centre Hospitalier Universitaire de Nantes, Nantes · Institut Curie, Paris · Institut Gustave Roussy, Villejuif
Registry updated 2026-11-03
NCT06743126
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Trial Treatment · Phase 3 · Immatics US, Inc.
Centre Hospitalier Universitaire de Lille, Lille · Assistance Publique Hopitaux de Paris, Paris · Institut Gustave Roussy, Villejuif
Registry updated 2026-10-30
NCT06953089
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Trial Treatment · Phase 2 · DualityBio Inc.
Institut de Cancerologie de l Ouest - Site Paul Papin - Departement d Oncologie - DÃ©partement d', Angers · Centre Georges François Leclerc, Dijon · Centre Léon Bérard - Oncologie Médicale, Lyon · Institut Paoli Calmettes - Hôpital de jour, Marseille · Fondation Hôpital Saint-Joseph, Paris · Centre Hospitalier Universitaire de Poitiers, Poitiers · Institut De Cancerologie De L Ouest, Saint-Herblain Cedex
Registry updated 2026-10-29
NCT06999499
Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D System.
Trial Treatment · Assistance Publique Hopitaux De Marseille
Hôpital de la Conception, Marseille
Registry updated 2026-10-28
NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Trial Treatment · Phase 2 · Daiichi Sankyo
CHU Bordeaux, Bordeaux · Centre Georges Franăois Leclerc, Dijon · Hopital Claude Huriez - Chu Lille, Lille · Centre Leon Berard, Lyon · Hăpital de La Timone, Marseille · Chu Nantes - Hătel Dieu, Nantes · Institut Claudius Regaud, Toulouse · ICL - Alexis Vautrin, Vandœuvre-lès-Nancy · Institut Gustave Roussy, Villejuif
Registry updated 2026-10-26
NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Trial Treatment · Phase 1/2 · Daiichi Sankyo
CHU Besancon, Besancon Cedex · Institut Bergonie, Bordeaux · Centre Hospitalier Universitaire De Bordeaux, Bordeaux Cedex · Centr Georges Francois Leclerc, Dijon · Centre Leon Berard, Lyon · Institut Regional Du Cancer De Montpellier, Montpellier Cedex 5 · Institut Curie, Paris · Centre De Lutte Contre Le Cancer Eugene Marquis, Rennes Cedex · Institut De Cancerologie De L Ouest, Saint-Herblain Cedex · Oncopole Claudius Regaud, Toulouse Cedex 9 · Institut Gustave Roussy, Villejuif
Registry updated 2026-10-26
NCT07376512
Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis
Research · Centre Georges Francois Leclerc
CHU Besançon - Service Pneumologie Oncologie Thoracique, Besançon · CHU Besançon - Service Dermatologie, Besançon · CHU Dijon - Service Oncologie Médicale, Dijon · Centre Georges François Leclerc, Dijon · Centre Leon Berard - Service Oncologie Médicale, Lyon
Registry updated 2026-10-26
NCT07883759
Neoadjuvant Pembrolizumab in Patients With High Risk, Stage IIB/IIC Cutaneous Melanoma: a Single Arm Proof of Concept Phase IIA Study.
Trial Treatment · Phase 2 · Centre Hospitalier Universitaire de Besancon
Centre Hospitalier Regional Universitaire, Besancon Cedex · Centre Hospitalier Universitaire de Dijon, Dijon
Registry updated 2026-10-20
NCT06697301
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Trial Treatment · Phase 2/3 · Eikon Therapeutics
Centre Hospitalier de la Cote Basque, Bayonne · Centre hospitalier Universitaire de Bordeaux, Bordeaux · Assistance Publique Hopitaux De Paris, Boulogne-Billancourt · Centre Hospitalier Universitaire Grenoble Alpes, Grenoble Cedex 9 · Centre Hospitalier Universitaire de Lille, Lille · Centre Hospitalier Regional De Marseille, Marseille · Centre Hospitalier Universitaire de Nice, Nice · Assistance Publique Hopitaux De Paris, Paris Cedex 18 · Hospices Civils de Lyon, Pierre-Bénite · Centre Hospitalier Universitaire Rouen, Rouen Cedex · Institut De Cancerologie De L Ouest, Saint-Herblain Cedex · Groupe Hospitalier Saint Vincent, Strasbourg
Registry updated 2026-10-06
NCT06961006
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Trial Treatment · Phase 2 · Merck Sharp & Dohme LLC
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Dermatology Department ( Site 2042), Nice · Hôpital Saint-Louis ( Site 2041), Paris · Gustave Roussy ( Site 2040), Villejuif
Registry updated 2026-09-28
NCT05727904
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Trial Treatment · Phase 3 · Iovance Biotherapeutics, Inc.
Institut Paoli-Calmettes, Marseille · Hospital Hotel Dieu, Nantes · Hopital Saint Louis, Paris
Registry updated 2026-09-24
NCT05059444
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Research · Guardant Health, Inc.
CHU Besançon, Besançon · Hôpital Franco-Britannique, Levallois-Perret · Institut Paoli-Calmettes, Marseille · Ambroise Paré-Hartmann, Neuilly · APHP Tenon Hospital - Sorbonne, Paris
Registry updated 2026-09-14
NCT04913285
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Trial Treatment · Phase 1 · Pierre Fabre Medicament
Institut Bergonie, Bordeaux · Centre François Baclesse, Caen · CHU de Lille, Lille · Centre Leon Berard, Lyon · APHM-CHU La Timone, Marseille · CHU Nantes-Hotel Dieu, Nantes · CHU de Nice - Hôpital Archet 2, Nice · APHP - Hôpital St Louis, Paris · Hospices Civiles de Lyon - Hôpital Lyon Sud, Pierre-Bénite · CHU de Poitiers, Poitiers · Oncopole Claudius Regaud, Toulouse · Gustave Roussy, Villejuif
Registry updated 2026-09-02
NCT07338968
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma
Research · Phase 3 · Aura Biosciences
Hospices Civils De Lyon, Lyon Cedex 04 · Centre Hospitalier Universitaire de Nice, Nice
Registry updated 2026-08-19
NCT05592626
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Trial Treatment · Phase 1/2 · Marengo Therapeutics, Inc.
Institute Gustave Roussy, Villejuif
Registry updated 2026-08-11
NCT07340619
Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
Trial Treatment · Phase 2 · UNICANCER
Institut Bergonie, Bordeaux · Centre Leon Berard, Lyon · Institut Paoli-Calmettes, Marseille · Centre Antoine Lacassagne, Nice Cedex 2 · Institut Curie, Paris · Centre De Lutte Contre Le Cancer Eugene Marquis, Rennes Cedex · Institut De Cancerologie De L Ouest, Saint-Herblain Cedex · Oncopole Claudius Regaud, Toulouse Cedex 9 · Institut Gustave Roussy, Villejuif
Registry updated 2026-08-03
NCT06627595
Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management
Research · University Hospital, Montpellier
Institut du Cancer de Montpellier (ICM), Montpellier · CHU de Montpellier, Montpellier
Registry updated 2026-07-28
NCT07230613
Neo-adjuvant Immunotherapy in Patients With Localized Melanoma
Trial Treatment · Phase 2 · UNICANCER
CHU de Bordeaux, Hôpital Saint-André, Bordeaux · Centre Leon Berard, Lyon · Hospices Civils de Lyon (Hôpital Lyon Sud), Lyon · AP-HM Marseille (Hôpital de la Timone), Marseille · AP-HP Hôpital Saint Louis, Paris · Gustave Roussy, Villejuif
Registry updated 2026-07-21
NCT06264180
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Trial Treatment · Phase 3 · Replimune, Inc.
Centre Hospitalier Universitaire De Bordeaux, Bordeaux Cedex · Centre Hospitalier Universitaire de Lille, Lille · Centre Hospitalier Regional De Marseille, Marseille · Centre Hospitalier Universitaire de Nice, Nice · Hopital Saint Louis, Paris · Hospices Civils de Lyon, Pierre-Bénite · Institut Gustave Roussy, Villejuif
Registry updated 2026-07-15
NCT02332668
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
Assistance Publique Hopitaux de Paris, Paris · Institut Gustave Roussy, Villejuif
Registry updated 2026-07-06
2025-521164-36-00
A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of TAX2 in patients with relapsed/refractory advanced/metastatic solid tumours
Trial Treatment · Phase 1/2 · Apmonia Therapeutics
Centre Leon Berard, Lyon · Institut Gustave Roussy, Villejuif
Registry updated 2026-07-01
NCT06246149
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Trial Treatment · Phase 3 · European Organisation for Research and Treatment of Cancer - EORTC
Centre Jean Perrin, Clermont Ferrand Cedex1 · Centre Antoine Lacassagne, Nice Cedex 2 · Institut Curie, Paris · Centre De Lutte Contre Le Cancer Eugene Marquis, Rennes Cedex
Registry updated 2026-06-30
NCT07354152
COmparison of the Use of a PERforator Flap Versus Total Skin GRAft in the Management of Loss of Substance After Resection of Cutaneous Melanoma - Pilot Study
Research · Nantes University Hospital
CHU Nantes-Department of Severe Burns and Aesthetic Surgery, Nantes
Registry updated 2026-06-24

All Melanoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error